Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 19;21(2):4.
doi: 10.1007/s11910-020-01090-y.

Early-Onset Alzheimer's Disease: What Is Missing in Research?

Temitope Ayodele  1   2   3 , Ekaterina Rogaeva  4 , Jiji T Kurup  1 , Gary Beecham  5 , Christiane Reitz  6   7   8   9
Affiliations
Review

Early-Onset Alzheimer's Disease: What Is Missing in Research?

Temitope Ayodele et al. Curr Neurol Neurosci Rep. .

Abstract

Purpose of review: Early-onset Alzheimer's disease (EOAD), defined as Alzheimer's disease (AD) occurring before age 65, is significantly less well studied than the late-onset form (LOAD) despite EOAD often presenting with a more aggressive disease progression. The aim of this review is to summarize the current understanding of the etiology of EOAD, their translation into clinical practice, and to suggest steps to be taken to move our understanding forward.

Recent findings: EOAD cases make up 5-10% of AD cases but only 10-15% of these cases show known mutations in the APP, PSEN1, and PSEN2, which are linked to EOAD. New data suggests that these unexplained cases following a non-Mendelian pattern of inheritance is potentially caused by a mix of common and newly discovered rare variants. However, only a fraction of this genetic variation has been identified to date leaving the molecular mechanisms underlying this type of AD and their association with clinical, biomarker, and neuropathological changes unclear. While great advancements have been made in characterizing EOAD, much work is needed to disentangle the molecular mechanisms underlying this type of AD and to identify putative targets for more precise disease screening, diagnosis, prevention, and treatment.

Keywords: Biomarkers; Early-onset Alzheimer’s disease; Epidemiology; Genetics; Neuropathology.

PubMed Disclaimer

Conflict of interest statement

Temitope Ayodele, Ekaterina Rogaeva, Jiji T. Kurup, Gary Beecham, and Christiane Reitz declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Representative APP mutations causing early-onset Alzheimer’s disease with or without hemorrhage or stroke (in red). All known pathogenic missense substitutions in APP are localized in or around the Aβ-domain encoded by exons 16 and 17. The protective APP variant (Ala673Thr) is indicated in green
See this image and copyright information in PMC

References

    1. World Health Organization 2019 10 facts on dementia 2019 [.
    1. Alzheimer’s Association 2019 Alzheimer’s disease facts and figures. Alzheimers Dement. 2019;15(3):321–387. - PubMed
    1. Wingo TS, Lah JJ, Levey AI, Cutler DJ. Autosomal recessive causes likely in early-onset Alzheimer disease. Arch Neurol. 2012;69(1):59–64. - PMC - PubMed
    1. Barber IS, Braae A, Clement N, Patel T, Guetta-Baranes T, Brookes K, et al. Mutation analysis of sporadic early-onset Alzheimer’s disease using the NeuroX array. Neurobiol Aging. 2017;49(215):e1–e8. - PMC - PubMed
    1. Szigeti K, Doody RS. Should EOAD patients be included in clinical trials? Alzheimers Res Ther. 2011;3(1):4. - PMC - PubMed

Publication types